Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04588480
Recruitment Status : Active, not recruiting
First Posted : October 19, 2020
Last Update Posted : April 30, 2021
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
BioNTech SE

Brief Summary:

This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults.

The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19:

  • As 2 doses, separated by 21 days
  • At a single dose level
  • In adults 20 to 85 years of age

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Infection COVID-19 Biological: BNT162b2 Other: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS
Actual Study Start Date : October 21, 2020
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : November 30, 2021

Arm Intervention/treatment
Experimental: BNT162b2
BNT162b2 (intramuscular injection)
Biological: BNT162b2
BNT162b2 (intramuscular injection)

Placebo Comparator: Placebo
Placebo (intramuscular injection)
Other: Placebo
Placebo (intramuscular injection)




Primary Outcome Measures :
  1. Percentage of participants reporting local reactions [ Time Frame: For 7 days after dose 1 and dose 2 ]
    Pain at the injection site, redness, and swelling as self-reported on electronic diaries.

  2. Percentage of participants reporting systemic events [ Time Frame: For 7 days after dose 1 and dose 2 ]
    Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as self-reported on electronic diaries.

  3. Percentage of participants reporting adverse events [ Time Frame: From dose 1 through 1 month after the last dose ]
    As elicited by investigational site staff

  4. Percentage of participants reporting serious adverse events [ Time Frame: From dose 1 through 12 months after the last dose ]
    As elicited by investigational site staff

  5. Percentage of subset participants with abnormal hematology and chemistry laboratory values [ Time Frame: 1 day after dose 1 ]
    As measured at the local laboratory

  6. Percentage of subset participants with abnormal hematology and chemistry laboratory values [ Time Frame: 7 days after dose 1 ]
    As measured at the local laboratory

  7. Percentage of subset participants with abnormal hematology and chemistry laboratory values [ Time Frame: 7 days after dose 2 ]
    As measured at the local laboratory

  8. Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between baseline and 1 day after dose 1 ]
    As measured at the local laboratory

  9. Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between baseline and 7 days after dose 1 ]
    As measured at the local laboratory

  10. Percentage of subset participants with grading shifts in hematology and chemistry laboratory assessments [ Time Frame: Between before dose 2 and 7 days after dose 2 ]
    As measured at the local laboratory

  11. SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs [ Time Frame: 1 month after dose 2 ]
    As measured at the central laboratory

  12. GMFR in SARS-CoV-2 serum neutralizing titers [ Time Frame: From before vaccination to 1 month after dose 2 ]
    As measured at the central laboratory

  13. SARS-CoV-2 S1-binding IgG levels, expressed as GMCs [ Time Frame: 1 month after dose 2 ]
    as measured at the central laboratory

  14. GMFR in SARS-CoV-2 S1-binding IgG levels [ Time Frame: From before vaccination to 1 month after dose 2 ]
    as measured at the central laboratory


Secondary Outcome Measures :
  1. SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs [ Time Frame: Through 1 year after dose 2 ]
    As measured at the central laboratory

  2. GMFR in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point [ Time Frame: Through 1 year after dose 2 from baseline ]
    As measured at the central laboratory

  3. SARS-CoV-2 S1-binding IgG levels, expressed as GMCs [ Time Frame: Through 1 year after dose 2 ]
    As measured at the central laboratory

  4. GMFR in SARS-CoV-2 S1-binding IgG levels from before vaccination to each subsequent time point [ Time Frame: Through 1 year after dose 2 from baseline ]
    As measured at the central laboratory

  5. GMR of the geometric mean of SARS-CoV-2 serum neutralizing titers to the geometric mean of SARS CoV 2 S1-binding IgG levels [ Time Frame: Through 1 year after dose 2 ]
    As measured at the central laboratory



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Japanese male or female participants between the ages of 20 and 85 years, inclusive, at randomization.
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving personal signed informed consent.

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  • Receipt of medications intended to prevent COVID-19.
  • Previous confirmed diagnosis of COVID-19.
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Previous vaccination with any coronavirus vaccine.
  • Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
  • Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  • Previous participation in other studies involving study intervention containing lipid nanoparticles.
  • Subset only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04588480


Locations
Layout table for location information
Japan
SOUSEIKAI Sumida Hospital
Sumida-ku, Tokyo, Japan, 130-0004
SOUSEIKAI PS Clinic
Fukuoka, Japan, 812-0025
Sponsors and Collaborators
BioNTech SE
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: BioNTech SE
ClinicalTrials.gov Identifier: NCT04588480    
Other Study ID Numbers: C4591005
First Posted: October 19, 2020    Key Record Dates
Last Update Posted: April 30, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes